Education:

1980 Ph.D., Pharmacology, Yale University

1980 M.D., Yale University School of Medicine

1974 B.A., Biophysics, magna cum laude, Amherst College

Publications:

Fritsch B, Stott JJ, Donofrio JJ, Rogawski MA. Treatment of early and late kainic-acid induced status epilepticus with the noncompetitive AMPA receptor antagonist GYKI 52466. Epilepsia 2009 July 20.

Fritsch B, Qashu F, Figueiredo TH, Aroniadou-Anderjaska V, Rogawski MA, Braga MF. Pathological alterations in GABAergic interneurons and reduced tonic inhibition in the basolateral amygdala during epileptogenesis. Neuroscience 2009 June 17.

Braga MF, Aroniadou-Anderjaska V, Li H, Rogawski MA. Topiramate reduces excitability in the basolateral amygdala by selectively inhibiting GluK1 (GluR5) kainate receptors on interneurons and positively modulating GABA-A receptors on principal neurons.J Pharmacol Exp Ther 2009 May 5.

Rogawski MA. Convection-enhanced delivery in the treatment of epilepsy. Neurotherapeutics 6:344–351, 2009.

Reddy DS, Rogawski MA. Neurosteroid replacement therapy for catamenial epilepsy. Neurotherapeutics 6:392–401, 2009.

Biagini G, Longo D, Baldelli E, Zoli M, Rogawski MA Bertazzoni G, Avoli M. Neurosteroids and epileptogenesis in the pilocarpine model: Evidence for a relationship between P450scc induction and length of the latent period. Epilepsia 50(Suppl. 1):53–58, 2009.

Rogawski MA. Antiepileptic drugs and migraine. In, Innovative drug development for headache disorders (Frontiers in Headache Research Series) (Olesen J and Ramadan N, eds.), Oxford University Press, pp. 153–178, 2008.

Rogawski MA. Brivaracetam: a rational drug discovery success story. British Journal of Pharmacology 154:1555–1557, 2008

Rogawski MA. Common pathophysiologic mechanisms in migraine and epilepsy. Archives of Neurology 65:709–714, 2008.

Rogawski MA, Johnson MR. Intrinsic severity as a determinant of antiepileptic drug refractoriness. Epilepsy Currents 8:127–130, 2008.

Rogawski MA, Bazil CW. New molecular targets for antiepileptic drugs: α2δ, SV2A, and Kv7/KCNQ/M potassium channels. Current Neurology and Neuroscience Reports 8:345–352, 2008.

Macdonald RL, Rogawski MA. Cellular effects of antiepileptic drugs. In, Epilepsy: A Comprehensive Textbook, Second Edition (Engel J, Jr. and Pedley TA, eds.), Wolters Kluwer/Lippincott Williams & Wilkins, Philadelphia, pp. 1433–1445, 2008.

Meldrum BS, Rogawski MA. Molecular targets for antiepileptic drug development. Neurotherapeutics 4:18–61, 2007.

Hartman AL, Gasior M, Vining EPG, Rogawski MA. Neuropharmacology of the ketogenic diet. Pediatric Neurology 36:281–292, 2007.

Theodore WH, Rogawski MA. Epilepsy: mechanisms of drug action and clinical treatment. In, Handbook of Contemporary Neuropharmacology (Sibley DR, Hanin I, Kuhar M and Skolnick P, eds.), John Wiley & Sons, Hoboken, New Jersey, pp. 403–441, 2007.

N'Gouemo P, Rogawski MA. Alcohol withdrawal seizures. In, Models of Seizures and Epilepsy (Pitkänen A, Schwartzkroin PA and Moshé SL, eds.), Elsevier Academic Press, Amsterdam, pp. 161–177, 2006.

Biagini G, Baldelli E, Longo D, Pradelli L, Zini I, Rogawski MA, Avoli M. Endogenous neurosteroids modulate epileptogenesis in a model of temporal lobe epilepsy. Experimental Neurology 201:519–524, 2006.

Rogawski MA. Diverse mechanisms of antiepileptic drugs in the development pipeline. Epilepsy Research 69:273–294, 2006.

Full text (pdf) versions of recent publications are available here.

PharmExperts interview on the role of neurosteroids in catamenial epilepsy is available here.